Tiotropium Bromide Anhydrite is a long-acting muscarinic antagonist (LAMA) and inhaled bronchodilator used mainly for maintenance treatment of chronic obstructive pulmonary disease (COPD). It is also used as add-on maintenance therapy for asthma in appropriate patients. The phrase “tiotropium bromide anhydrous” refers to the water-free salt, while many marketed pharmaceutical products use tiotropium bromide monohydrate.
Tiotropium is not a rescue medicine for sudden bronchospasm. It is administered once daily through inhalation devices to maintain airway relaxation, improve lung function, and reduce COPD exacerbations. The best-known brand is Spiriva, available as HandiHaler dry powder and Respimat soft-mist inhalation products.
Chemical Structure
“Tiotropium Bromide Anhydrite” is a quaternary ammonium derivative structurally related to atropine and scopolamine. Its IUPAC name is (1α,2β,4β,7β)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.0²,⁴]nonane bromide.
The anhydrous form has the molecular formula and a molecular weight of approximately 472.41 g/mol. Its commonly cited CAS number is 136310-93-5. Tiotropium Bromide Anhydrite monohydrate has the same active molecular structure plus one water molecule, a molecular weight of approximately 490.43 g/mol, and CAS number 411207-31-3.
The permanently charged quaternary ammonium group limits penetration across biological membranes and helps confine the medicine mainly to the airway surface after inhalation.
Tiotropium-Based Medicines: Top Eight
Representative products include:
- Spiriva HandiHaler.
- Spiriva Respimat.
- Tiotropium bromide inhalation powder.
- Generic tiotropium inhalation capsules.
- Tiotropium bromide inhalation spray.
- Stiolto Respimat, containing tiotropium and olodaterol.
- Spiolto Respimat, the international name for tiotropium and olodaterol.
- Tiotropium/olodaterol generic inhalation products.
Combination products contain additional long-acting bronchodilators and have separate indications. Inhalation capsules must be used with the appropriate device and should never be swallowed.
Mechanism of Action
Tiotropium Bromide Anhydrite competitively antagonizes muscarinic acetylcholine receptors in airway smooth muscle. It has clinically important activity at M1, M2, and M3 receptors, with prolonged functional blockade of M3 receptors in the airways.
Acetylcholine normally stimulates muscarinic receptors and causes bronchial smooth-muscle contraction and mucus secretion. By blocking this pathway, tiotropium relaxes airway smooth muscle, reduces bronchoconstriction, and decreases mucus-related airflow limitation. Its slow dissociation from M3 receptors supports bronchodilation for approximately 24 hours.
Because it is long acting, Tiotropium Bromide Anhydrite is intended for regular maintenance use rather than immediate relief. A short-acting rescue inhaler is generally required for acute symptoms.
Pharmacokinetics
Tiotropium Bromide Anhydrite is delivered directly to the lungs, but only a fraction of the inhaled dose reaches the lower respiratory tract. Absolute inhaled bioavailability is approximately 19.5%. Peak plasma concentrations are reached shortly after inhalation, although the clinical effect is primarily local in the airways.
Tiotropium Bromide Anhydrite undergoes limited metabolism. Approximately 25% of a dose may be metabolized through CYP2D6 and CYP3A4 pathways, while most of the drug is eliminated unchanged through the kidneys. The terminal elimination half-life is approximately five to six days.
Renal impairment increases systemic exposure. Current labeling advises close monitoring for anticholinergic adverse effects in patients with moderate to severe renal impairment, particularly when creatinine clearance is below 60 mL/min.
Therapeutic Uses
| Condition | Therapeutic role | Important considerations |
|---|---|---|
| COPD | Long-term maintenance bronchodilation | Used once daily to improve airflow |
| Chronic bronchitis | Reduces bronchospasm and airflow limitation | Does not cure the underlying disease |
| Emphysema | Maintains bronchodilation | Used regularly, not only when symptoms occur |
| COPD exacerbation reduction | Helps reduce future exacerbations | Does not treat an acute exacerbation |
| Asthma | Add-on maintenance treatment | Used when symptoms persist despite controller therapy |
| Asthma in children | Respimat is approved for selected age groups | Age limits vary by country |
| Combination COPD therapy | Combined with olodaterol or other bronchodilators | Product-specific dosing applies |
| Exercise-related airflow limitation | May improve baseline lung function | Not a substitute for a rescue inhaler |
Spiriva HandiHaler was approved in the United States in 2004 for once-daily maintenance treatment of COPD, including chronic bronchitis and emphysema. Spiriva Respimat later received COPD and asthma indications, including pediatric asthma indications in current U.S. labeling.
Side Effects
Common adverse effects include dry mouth, constipation, sore throat, cough, headache, and sinus-related symptoms. Dry mouth is the most characteristic anticholinergic effect and may increase the risk of dental problems if persistent.
Serious reactions may include paradoxical bronchospasm, hypersensitivity, angioedema, blurred vision, increased eye pressure, urinary retention, palpitations, and tachycardia. Tiotropium powder accidentally entering the eyes can worsen narrow-angle glaucoma or cause eye pain and visual halos.
Patients should seek urgent medical help for sudden breathing difficulty immediately after inhalation, facial swelling, severe eye pain, inability to urinate, or rapid heartbeat.
Drug Interactions
Tiotropium Bromide Anhydrite has few clinically important metabolic drug interactions because it is primarily eliminated by the kidneys and has limited metabolism. However, it should not be used together with other anticholinergic medicines unless specifically directed, because additive effects may cause excessive dry mouth, constipation, urinary retention, blurred vision, or increased heart rate.
Cimetidine increased tiotropium exposure by approximately 20% and reduced renal clearance by about 28% in a pharmacokinetic study, although the clinical significance is usually limited. Ranitidine did not significantly affect tiotropium pharmacokinetics.
Safety Considerations
Tiotropium Bromide Anhydrite is contraindicated in patients with serious hypersensitivity to tiotropium, ipratropium, atropine-like medicines, or formulation ingredients. It should be used cautiously in narrow-angle glaucoma, prostate enlargement, bladder-outflow obstruction, kidney impairment, arrhythmias, and severe cardiovascular disease.
The inhaler technique is important. HandiHaler capsules must be placed into the device and punctured before inhalation; they must not be swallowed. Respimat requires correct cartridge insertion, priming, and spray technique. Patients should continue prescribed inhaled corticosteroids or other controller medicines unless told otherwise.
Tiotropium Bromide Anhydrite does not provide immediate relief during a severe attack. Patients should maintain access to a prescribed short-acting rescue inhaler and seek emergency care for severe breathlessness, cyanosis, confusion, or poor response to rescue therapy.
Regulatory Status
Spiriva HandiHaler received initial U.S. FDA approval on January 30, 2004, for long-term maintenance treatment of COPD. Spiriva Respimat received U.S. approval for COPD in 2014 and later gained asthma indications.
Tiotropium Bromide Anhydrite is approved internationally in dry-powder capsules, soft-mist inhalers, and combination products. Regulatory status, approved age groups, dosage strengths, and renal warnings vary by country. The marketed drug substance may be tiotropium bromide monohydrate even when product descriptions refer broadly to tiotropium bromide.
Conclusion
Tiotropium Bromide Anhydrite is a long-acting inhaled antimuscarinic that provides approximately 24-hour bronchodilation for COPD and selected asthma patients. Its quaternary ammonium structure limits systemic penetration, while prolonged M3-receptor blockade supports once-daily maintenance therapy. Correct inhaler use, monitoring for anticholinergic effects, caution in renal impairment, and avoidance of duplicate anticholinergic therapy are essential for safe treatment.
